Azilsartan Circadian and Sleep Pressure

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by Sogo Rinsho Médéfi Co., Ltd.
Sponsor:
Collaborator:
Takeda
Information provided by (Responsible Party):
Sogo Rinsho Médéfi Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01762501
First received: December 18, 2012
Last updated: April 22, 2013
Last verified: January 2013

December 18, 2012
April 22, 2013
December 2012
September 2013   (final data collection date for primary outcome measure)
Change in nocturnal systolic blood pressure level [ Time Frame: Baseline and 8 weeks ] [ Designated as safety issue: No ]

Change at the end of a treatment period (Week 8) from the beginning point of an observation period

*Nocturnal systolic blood pressure level: the mean value of systolic arterial pressure during night (during sleeping)

Same as current
Complete list of historical versions of study NCT01762501 on ClinicalTrials.gov Archive Site
Efficacy [ Time Frame: Baseline and 8 weeks ] [ Designated as safety issue: No ]
  • Change in the absolute value in difference with targeted value* (15 percent) of nocturnal systolic blood pressure fall**
  • Change in nocturnal diastolic blood pressure level
  • Change in 24-hour mean systolic blood pressure level
  • Change in 24-hour mean diastolic blood pressure level
  • Change in urinary micro albumin excretion
  • Change in N-terminal pro-B-type natriuretic peptide (NT-proBNP)
  • Change in high-sensitivity cardiac troponin T (hs-cTnT)
  • Change in fasting glucose
  • Change in insulin resistance index***

    • The targeted value has been set as the median of the dipping rate, normal type of nocturnal blood pressure variation, rate of nocturnal blood pressure fall (10-20 percent) ** Rate of nocturnal blood pressure fall: calculated as (awake SBP-sleep SBP)/awake SBP *** Insulin resistance index = fasting insulin level x fasting glucose level / 405
Same as current
Safety [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Adverse event

- For Safety Analysis Set (SAS), count the onset rate of adverse events in term from the start of treatment period (Week 0) to the end (Week 8) in each group

Same as current
 
Azilsartan Circadian and Sleep Pressure
Azilsartan Circadian and Sleep Pressure - the 1st Study

To determine the efficacy of Azilsartan 20 mg versus Amlodipine 5 mg oral administration once per day for 8 weeks in patients with grade I or grade II essential hypertension.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Hypertension
  • Drug: Azilsartan
    Azilsartan 20mg/day
  • Drug: Amlodipine
    Amlodipine 5mg/day
  • Experimental: Azilsartan
    Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
    Intervention: Drug: Azilsartan
  • Active Comparator: Amlodipine
    Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
    Intervention: Drug: Amlodipine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
700
Not Provided
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Grade I or II essential hypertension
  • The sitting systolic blood pressure is in term of 140-179 mmHg, or sitting diastolic blood pressure is in term of 90-109 mmHg at the both two time points at the beginning of the observation period and at the beginning of a treatment period (Week0)
  • 20 years old or older at the time of the informed consent
  • Able to give written informed consent before participating in the research
  • Therapeutic category during the observation period: Ambulatory

Exclusion Criteria:

  • Secondary hypertension, grade III hypertension (sitting systolic blood pressure greater than or equal to 180 mmHg or sitting diastolic blood pressure greater than or equal to 110 mmHg), malignant hypertension
  • More than 2 kinds of antihypertensive agents for treatment on the hypertension
  • History of taking following medicines within 2 weeks before start of the observation period.

When subject with taking any of the following medicine at the time of informed consent is included, stop to take the medicine for determined period after the informed consent.

I. Antihypertensive agents II. Antianginal agents III. Antiarrhythmic agents (except single time use of the lidocaine hydrochloride formulation for anesthesia) IV. Digitalis products

  • Less than 130 mmHg of mean 24-hour systolic blood pressure and less than 80 mmHg of mean 24-hour diastolic blood pressure at the start of the observation period.
  • History of following circulatory-related diseases or symptoms within 24 weeks before start of the observation period.

I. Cardiac disease: Myocardial infarction, coronary artery revascularization II. Cerebrovascular-disease: cerebral infarction, cerebral hemorrhage, transient ischemic attack III. Progressive hypertensive retinopathy: hemorrhage, exudation, or papilledema

  • History or complication with the following circulatory-related diseases; Valvular stenosis, atrial fibrillation, pharmacotherapy-required angina, congestion heart failure, or cardiac arrhythmia, or arteriosclerosis obliterans with symptoms of intermittent claudication et al
  • Day / night reversal
  • History of hypersensitivity or allergy to Azilsartan, Amlodipine, or related drugs
  • Participant in any other clinical research
  • Pregnant, possible to being pregnant, or lactating woman
  • Mal-control of blood pressure during informed consent to taking antihypertensive agent
  • Any those the investigator or other researchers consider as unsuitable
Both
20 Years and older
No
Contact: Kazuo Kario 81-285-58-7538
Japan
 
NCT01762501
ACS1
Not Provided
Sogo Rinsho Médéfi Co., Ltd.
Sogo Rinsho Médéfi Co., Ltd.
Takeda
Not Provided
Sogo Rinsho Médéfi Co., Ltd.
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP